Darja Arko

Dr. Darja Arko

Divison of Gynecology and Perinatology, University Medical Centre Maribor, 2000 Maribor, Slovenia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Clinica Chimica Acta
Verified
Journal Article
Closed access
NKNejc Kozar
Nejc Kozar
KKKristi Kruusmaa
Kristi Kruusmaa
MBMarko Bitenc
Marko Bitenc
RARosa Argamasilla
Rosa Argamasilla
AAAntonio Adsuar
Antonio Adsuar
Iztok TakačIztok Takač
Iztok Takač

1 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MBMaša Brumec
Maša Brumec
Monika SobocanMonika Sobocan
Monika Sobocan
Iztok TakačIztok Takač
Iztok Takač
Darja ArkoDarja Arko
Darja Arko
This review summarizes the recent findings of a vast array of studies conducted on androgen receptor-positive triple-negative breast cancer (AR-positive TNBC) to provide a better understanding of this specific breast cancer subgroup. AR expression is correlated with higher age, lower histological grade, lower proliferation index Ki-67, spiculated masses, and calcifications on mammography. Studies investigating the correlation between AR expression and lymph node metastasis are highly discordant. In addition, results regarding prognosis are highly contradictory. AR antagonists are a promising novel therapeutic approach in AR-positive TNBC. However, AR signaling pathways should be more investigated in order to understand the influence of AR expression on TNBC more thoroughly.

17 December 2019 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
Kristijan SkokKristijan Skok
Kristijan Skok
Uroš MaverUroš Maver
Uroš Maver
LGLidija Gradišnik
Lidija Gradišnik
NKNejc Kozar
Nejc Kozar
Iztok TakačIztok Takač
Iztok Takač
Darja ArkoDarja Arko
Darja Arko

6 January 2021 in Radiology and Oncology
Verified
Journal Article
Open access
PDF file
TBTeodora Bokan
Teodora Bokan
UIUrska Ivanus
Urska Ivanus
TJTine Jerman
Tine Jerman
ITIztok Takac
Iztok Takac
Darja ArkoDarja Arko
Darja Arko
Background: We are presenting the results of the Slovenian human papillomaviruses (HPV) self-sampling pilot study in colposcopy population of National Cervical Cancer Screening Programme ZORA for the first time. One-year and four-year follow-up results are presented for two different self-sampling devices. Participants and methods: A total of 209 women were enrolled in the study at colposcopy clinic. Prior to the gynaecological examination, all women performed self-collected vaginal swab at the clinic; 111 using Qvintip and 98 using HerSwab self-sampling device. After self-sampling, two cervical smears were taken by a clinician; first for conventional cytology and second for HPV test. After that, all women underwent colposcopy and a cervical biopsy if needed. We compared sensitivity, specificity, and predictive values of cytology (at the cut-off atypical squamous cells of undetermined significance or more [ASC-US+]) and HPV test (on self- and clinician-taken samples) for the detection of cervical intraepithelial neoplasia grade 2 or more (CIN2+) after one and four years of follow-up. Hybrid Capture 2 (HC2) assay was used for all HPV testing. Results: The mean age of 209 women was 37.6 years and HPV positivity rate 67.0% (140/209), 36.9 years and 70.3% (78/111) in the Qvintip group and 38.4 years and 63.3% (62/98) in the HerSwab group, respectively. Overall, percent agreement between self and clinician-taken samples was 81.8% (kappa 0.534) in the Qvintip and 77.1% (kappa 0.456) in the HerSwab group. In the Qvintip group, the longitudinal sensitivity, specificity, positive and negative predictive values were 71.8%, 75.0%, 83.6%, 60.0% for cytology; 83.1%, 51.3%, 75.6% and 62.5% for HPV test of self-taken samples and 94.4%, 57.5%, 79.8% and 85.2% for HPV test on clinician-taken samples. In the HerSwab group, the corresponding results were 71.7%, 46.7%, 61.3%, 58.3% for cytology; 75.0%, 47.7%, 62.9% and 61.8% for HPV test on self-taken samples and 94.3%, 44.4%, 66.7% and 87.0% for clinician-taken samples, respectively. Conclusions: The results confirm that HPV self-sampling is not as accurate as clinician sampling when HC2 is used. All HPV tests showed a higher sensitivity in detecting CIN2+ compared to cytology. Due to non-inferior longitudinal sensitivity of HPV self-sampling compared to cytology, HPV self-sampling might be an option for non-attenders to the National Cancer Screening Programme.

1 June 2018 in Data in Brief
Verified
Journal Article
Open access
NKNejc Kozar
Nejc Kozar
KKKristi Kruusmaa
Kristi Kruusmaa
MBMarko Bitenc
Marko Bitenc
RARosa Argamasilla
Rosa Argamasilla
AAAntonio Adsuar
Antonio Adsuar
Iztok TakačIztok Takač
Iztok Takač
The data presented here are related to the research paper entitled "Metabolomic profiling suggests long chain ceramides and sphingomyelins as a possible diagnostic biomarker of epithelial ovarian cancer." (Kozar et al., 2018) [1]. Metabolomic profiling was performed on 15 patients with ovarian cancer, 21 healthy controls and 21 patients with benign gynecological conditions. HPLC-TQ/MS was performed on all samples. PLS-DA was used for the first line classification of epithelial ovarian cancer and healthy control group based on metabolomic profiles. Random forest algorithm was used for building a prediction model based over most significant markers. Univariate analysis was performed on individual markers to determine their distinctive roles. Furthermore, markers were also evaluated for their biological significance in cancer progression.